DK2450056T3 - Forebyggelse og behandling af synucleinopatisk og amyloidogen sygdom - Google Patents
Forebyggelse og behandling af synucleinopatisk og amyloidogen sygdom Download PDFInfo
- Publication number
- DK2450056T3 DK2450056T3 DK11175183.0T DK11175183T DK2450056T3 DK 2450056 T3 DK2450056 T3 DK 2450056T3 DK 11175183 T DK11175183 T DK 11175183T DK 2450056 T3 DK2450056 T3 DK 2450056T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- synuclein
- alpha
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (10)
1. Antistof der binder til human alpha-synuclein til anvendelse til profylakse eller behandling af en Lewy body sygdom, hvor antistoffet er: det 8A5-monoklonale antistof produceret af hybridomacellen med ATCC-accessionsnummer PTA-6909; en kimær form af 8A5-antistoffet; eller en humaniseret version af 8A5-antistoffet omfattende CDR'erne fra 8A5-antistoffet.
2. Antistof til anvendelse ifølge krav 1, hvor antistoffet er et antistof af human IgGl-isotype.
3. Antistof til anvendelse ifølge krav 1 eller krav 2, hvor antistoffet indgives i en dosis på 1 mg til 100 mg antistof per kg kropsvægt.
4. Antistof til anvendelse ifølge et hvilket som helst af de foregående krav, hvor antistoffet indgives i flere doser over mindst seks måneder.
5. Antistof til anvendelse ifølge et hvilket som helst af de foregående krav, hvor antistoffet indgives intraperitonealt, oralt, subkutant, intrakranialt, intramuskulært, topikalt, intranasalt eller intravenøst.
6. Hybridomacelle med ATCC accessionsnummer PTA-6909.
7. Farmaceutisk sammensætning omfattende et kimært eller humaniseret antistof ifølge krav 1.
8. Fremgangsmåde til humanisering af det monoklonale antistof 8A5 produceret af hybridomacellen med ATCC-accessionsnummer PTA-6909, omfattende: at bestemme aminosyresekvensen af CDR'erne af det monoklonale antistof; at udvælge et acceptor-antistof; og at producere et humaniseret antistof omfattende CDR'erne fra det monoklonale antistof og variable region-skelet fra acceptor-antistoffet, eventuelt hvor fremgangsmåden endvidere omfatter at substituere en udvalgt rest fra human variabel region-skelet med en tilsvarende skelet-aminosyre fra 8A5-antistoffet når aminosyren (1) ikke-kovalent binder antigen direkte, (2) støder op til en CDR-region af antistoffet, (3) på anden måde interagerer med en CDR-region af antistoffet, eller (4) deltager i VL-VH-grænsefladen, eller at substituere en human skelet-aminosyre der er usædvanlig for en human immunglobulin i den position med en aminosyre fra den tilsvarende position af 8A5-antistoffet eller fra den tilsvarende position afen mere typisk human immunglobulin.
9. Fremgangsmåde til fremstilling afen kimær form af det monoklonale antistof 8A5 produceret af hybridomacellen med ATCC-accessionsnummer PTA-6909, omfattende: at bestemme aminosyresekvensen aflet- og tungkæde variabelregionerne af det monoklonale antistof; at udvælge tung- og letkæde konstantregion; at producere et kimært antistof omfattende en letkæde omfattende letkæde variabelregionen fusioneret med letkæde konstantregionen, og en tungkæde omfattende tungkæde variabelregionen fusioneret med tungkæde konstantregionen.
10. Antistof til anvendelse ifølge krav 1, hvor sygdommen er Parkinsons sygdom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/185,907 US8506959B2 (en) | 2002-11-01 | 2005-07-19 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
PCT/US2005/028166 WO2006020581A2 (en) | 2004-08-09 | 2005-08-09 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP06800177.5A EP1910829B1 (en) | 2005-07-19 | 2006-07-19 | Prevention and treatment of synucleinopathic and amyloidogenic disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2450056T3 true DK2450056T3 (da) | 2017-05-22 |
Family
ID=37669570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11175183.0T DK2450056T3 (da) | 2005-07-19 | 2006-07-19 | Forebyggelse og behandling af synucleinopatisk og amyloidogen sygdom |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1910829B1 (da) |
CA (1) | CA2616047C (da) |
DK (1) | DK2450056T3 (da) |
EA (1) | EA013752B1 (da) |
MX (1) | MX2007001679A (da) |
WO (1) | WO2007012061A2 (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
WO2008103472A2 (en) * | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
EP3239175A1 (en) | 2007-01-05 | 2017-11-01 | University of Zurich | Method of providing disease-specific binding molecules and targets |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
EP3067066B1 (en) * | 2007-02-23 | 2019-03-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
SI2949666T1 (sl) | 2008-12-19 | 2019-03-29 | Biogen International Neuroscience Gmbh | Človeška anti alfa-sinukleinska protitelesa |
AT508638B1 (de) * | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
JP6061922B2 (ja) * | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
KR102202925B1 (ko) * | 2013-11-21 | 2021-01-14 | 에프. 호프만-라 로슈 아게 | 항-알파-시누클레인 항체 및 사용 방법 |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
EP4000632A1 (en) | 2016-06-02 | 2022-05-25 | MedImmune Limited | Antibodies to alpha-synuclein and uses thereof |
MX2019005594A (es) | 2016-11-15 | 2019-07-04 | H Lundbeck As | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. |
BR112018016717A2 (pt) * | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
CA3049110A1 (en) * | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
MX2019008029A (es) * | 2017-01-06 | 2019-12-11 | Abl Bio Inc | Anticuerpo anti-alfa-sinucleina y su uso. |
KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE |
US11655289B2 (en) | 2017-08-22 | 2023-05-23 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0600866T3 (da) | 1990-06-01 | 1998-03-09 | Chiron Corp | Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler |
US5593970A (en) | 1990-06-11 | 1997-01-14 | Biochem Pharma Inc. | Heterocyclic anthracycline analogs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
ES2097925T3 (es) | 1991-09-18 | 1997-04-16 | Affymax Tech Nv | Metodo para sintetizar diversas colecciones de oligomeros. |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5314992A (en) | 1991-11-25 | 1994-05-24 | Trustees Of Dartmouth College | Lipocortin-1 receptor protein and its uses |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
CA2143848C (en) | 1992-10-01 | 2007-09-11 | W. Clark Still | Complex combinatorial chemical libraries encoded with tags |
WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
CA2169635C (en) | 1993-08-26 | 2002-11-12 | Dennis A. Carson | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
PT735893E (pt) | 1993-09-14 | 2009-03-06 | Pharmexa Inc | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária |
AU703472B2 (en) | 1993-11-02 | 1999-03-25 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
JPH10500112A (ja) | 1994-05-06 | 1998-01-06 | ファーマコピーア,インコーポレイテッド | 組合せ ジヒドロベンゾピラン ライブラリー |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
WO1997017614A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
WO1998025386A2 (en) | 1996-12-03 | 1998-06-11 | Northern Telecom Limited | System connecting remote agents over standard telephone lines |
JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用 |
AU8163798A (en) | 1997-06-25 | 1999-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cloning of a gene mutation for parkinson's disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7276643B2 (en) | 2000-02-18 | 2007-10-02 | The Regents Of The University Of California | Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents |
KR20020097241A (ko) * | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
WO2002075317A2 (en) * | 2001-03-15 | 2002-09-26 | Novartis Ag | Screening for drugs against disorders associated with schizophrenia |
AU2002345843A1 (en) | 2001-06-22 | 2003-01-08 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
CA2466841A1 (en) * | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
DK2361928T3 (da) | 2003-05-19 | 2017-07-03 | Prothena Biosciences Ltd | Trunkerede fragmenter af alpha-synuklein i Lewy body-sygdom |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
-
2005
- 2005-08-09 EA EA200700427A patent/EA013752B1/ru active Application Revival
- 2005-08-09 MX MX2007001679A patent/MX2007001679A/es active IP Right Grant
-
2006
- 2006-07-19 CA CA2616047A patent/CA2616047C/en active Active
- 2006-07-19 EP EP06800177.5A patent/EP1910829B1/en not_active Revoked
- 2006-07-19 EP EP11175183.0A patent/EP2450056B1/en active Active
- 2006-07-19 WO PCT/US2006/028273 patent/WO2007012061A2/en active Search and Examination
- 2006-07-19 DK DK11175183.0T patent/DK2450056T3/da active
Also Published As
Publication number | Publication date |
---|---|
EP1910829A2 (en) | 2008-04-16 |
WO2007012061A2 (en) | 2007-01-25 |
CA2616047C (en) | 2018-01-09 |
EA013752B1 (ru) | 2010-06-30 |
EA200700427A1 (ru) | 2008-02-28 |
EP2450056A1 (en) | 2012-05-09 |
EP1910829B1 (en) | 2016-03-02 |
MX2007001679A (es) | 2007-05-23 |
EP1910829A4 (en) | 2009-04-22 |
EP2450056B1 (en) | 2017-03-15 |
WO2007012061A3 (en) | 2007-12-13 |
CA2616047A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2450056T3 (da) | Forebyggelse og behandling af synucleinopatisk og amyloidogen sygdom | |
US20210032318A1 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
DK1793855T3 (da) | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom | |
EP2118300B1 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
US7919088B2 (en) | Treatment and delay of onset of synucleinopathic and amyloidogenic disease | |
US20090208487A1 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
DK2118300T3 (da) | Forebyggelse og behandlng af synukleinopatisk og amyloidogen sygdom | |
US20160184416A1 (en) | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease | |
DK2583978T3 (da) | Forebyggelse og behandling af synucleinopatiske og amyloidogene sygdomme |